CytoArm Receives IRB Approval for Phase I Clinical Trial on Novel Immunotherapy for Metastatic Colorectal Cancer

CytoArm is proud to announce a major milestone: approval from the SingHealth Centralised Institutional Review Board (CIRB) to initiate our first-in-human, open-label Phase I clinical trial. This trial will evaluate the safety and tolerability of our innovative therapeutic, CTA-002, in patients with refractory or relapsed EGFR+ metastatic colorectal cancer (mCRC).

Addressing an Unmet Need

Our novel therapy, CTA-002, addresses a significant unmet medical need in patients who face limited treatment options due to refractory or relapsed EGFR+ mCRC. With colorectal cancer being a leading cause of cancer-related deaths globally, and 25-50% of patients exhibiting EGFR+ mutations, the market potential for CTA-002 is considerable. If successful, CTA-002 could offer a safer, more effective treatment option for patients with this aggressive cancer type.

Major Milestone Achieved

This approval from Singapore’s National Cancer Centre marks a pivotal moment for CytoArm. The initiation of this first-in-human trial represents a significant step toward offering a potentially life-changing therapy. As we progress into patient recruitment and study initiation, this achievement strengthens our position as a leader in cutting-edge immunotherapy development.

Backed by Expertise and Collaboration

CytoArm’s dedicated team of scientists, and researchers are committed to advancing the future of cancer treatment. Our collaboration with the prestigious National Cancer Centre Singapore underscores the depth of our expertise and commitment to delivering groundbreaking therapies.

Future Outlook and Investment Opportunity

With the Phase I trial ready to launch, CytoArm is poised for rapid progress toward future clinical milestones. This trial serves as a critical foundation for further development and commercial potential. We are excited about the possibilities ahead and invite investors to partner with us in this mission to revolutionize cancer therapy.

For more information on how you can be part of this groundbreaking journey, please contact us at Contact – CYTOARM 賽昂生醫.